-
Has invested in innovative projects such as Ascentage and Zhenzhen, and won 5 new drugs, what kind of companies does this institution favor when investing
Time of Update: 2023-01-05
Since the launch of the Science and Technology Innovation Board, the marketization of valuation has become more and more obvious, promoting new discoveries in the value of the biomedical industry, and also testing the insight of investment institutions into the future development of enterprises and their forward-looking judgment on corporate value.
-
The Lancet: BA.1, BA.4, BA.5 and Q.1.1 are resistant to all therapeutic antibodies
Time of Update: 2022-12-30
1. 1 resistance to monoclonal antibodies Are currently approved antibody therapies for the treatment of patients at high risk of severe COVID-19 disease also effective against virus variants currently circulating?
-
Lancet: Professor Liu's team found lower limit of blood pressure management after thrombectomy and recanalization in stroke patients (ENCHANTED-2/MT study
Time of Update: 2022-11-04
On October 28, the main issue of the international top journal "Lancet" magazine published online the latest results of the clinical research of Professor Liu Jianmin of Changhai Hospital of Naval Mil
-
In 2022, the overall investment and financing trend in the medical and health field will slow down
Time of Update: 2022-10-20
In recent years, the research and development of domestic innovative drugs has been hot, but the targets are piled up, the track is crowded, and the involution is serious, which has caused the development of the innovative drug industry to fall into a bottleneck period, coupled with the impact of medical insurance control fees, the epidemic and other factors, the investment and financing in the domestic medical and health field are "deserted" compared with last year.
-
Express treatment of prostate cancer, Pfizer PARP inhibitor combination therapy reached the main clinical endpoint of Phase 3
Time of Update: 2022-10-13
▎Editor of WuXi AppTec content teamPfizer today announced that its combination therapy of PARP inhibitor Talzenna (talazoparib) and Xtandi (enzalutamide) has achieved positive results in the TALAPRO-2
-
More than half of pharmaceutical companies have achieved performance growth, and the CXO field will benefit in the long run
Time of Update: 2022-09-08
In addition to WuXi AppTec, the net profit attributable to the parent of CXO companies such as Boteng Shares, Gloria Ying, Baicheng Pharmaceutical, and Yaokang Biotech has increased by more than 50% year-on-year.
-
New DNA repair method successfully repairs disease-causing gene mutation in patient's kidney cells
Time of Update: 2022-08-19
By applying synthetic biology techniques, a research team led by Dr Francesco Aulicino and Professor Imre Berger from the University of Bristol's School of Biochemistry has redesigned the baculovirus, an insect virus that is harmless to humans and no longer limited in "cargo" capacity .
-
Prof. Li Yuhua: Advances and Prospects of Drug Therapy for Indolent Lymphoma 2021 China Oncology Congress
Time of Update: 2022-06-08
Summary Professor Li Yuhua finally concluded that in the field of indolent lymphoma treatment, the chemotherapy regimen containing CD20 monoclonal antibody is the cornerstone of treatment, and the multi-target drug combination research carried out on this basis has significantly improved the remission rate and remission of relapsed and refractory patients.
-
Recently, local pharmaceutical companies have successively reviewed a number of large varieties of drugs
Time of Update: 2022-05-18
Data shows that in 2020, the market size of the terminal piracetam injection in China's public medical institutions is close to 2 billion yuan, a year-on-year increase of 37.
-
In 2021, the performance of domestic CRO/CDMO manufacturers is sorted out, and the industry development trend
Time of Update: 2022-04-25
Heyuan Bio, Wea Bio, Medici Bio, Pioneer Bio and Boji Bio, GenScript Bio In general, the CRO and CDMO businesses of leading companies have grown rapidly, and the popularity and valuation of this vertical capital are very high .
-
Fudan University's Nature Long Article Released: Building a Global Catalog of Microbial Genes
Time of Update: 2022-01-26
, collecting 13,174 publicly available high-quality metagenomes and 84,029 high-quality Genomes of high quality, including 303 million species-level genes (95% nucleic acid consistency clustering), have constructed the most comprehensive global microbial gene catalog (Figure 1) to date, which will be used for earth ecology research and human health research.
-
HER3-targeted ADC is recognized as a breakthrough therapy for the treatment of patients with drug-resistant non-small cell lung cancer
Time of Update: 2022-01-10
This is a potential "first-in-class" HER3 targeting antibody conjugate drug (ADC), used for the treatment of third-generation tyrosine kinase inhibitors (TKI) and platinum-containing therapy during or during treatment Later, patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) who have disease progression and carry drug-resistant EGFR mutations .
-
Zero death
Time of Update: 2021-12-05
Phase III clinical trial results showed that compared with placebo, patients who received intravenous Ronapreve had a 70% lower risk of hospitalization or death.
Celltrion's Regkirona global phase III clinical trial data showed that compared with placebo, patients treated with Regkirona have a 70% lower risk of hospitalization or death .
-
Better efficacy than topiramate! Novartis/Amgen Aimovig head-to-head Phase 4 clinical results announced
Time of Update: 2021-12-03
Aimovig is the world's first migraine drug that targets the calcitonin-related gene peptide (CGRP) target and is jointly commercialized by Novartis and Amgen in the United States .
-
The world's first human permanent neonatal diabetic canine model comes out
Time of Update: 2021-11-12
Photo courtesy of Lai Liangxue team Injection of exogenous insulin to treat permanent neonatal diabetic model dogs, homozygous mutants on the left, chimeric mutants on the right .
